You have 9 free searches left this month | for more free features.

Pharmacyclics

Showing 1 - 25 of 110

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)

Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
Oct 19, 2022

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)

Completed
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
  • +1 more
Dec 5, 2022

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • New York, New York
  • +1 more
Nov 8, 2022

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • MYD88 Gene Mutation
  • Boston, Massachusetts
  • +1 more
Apr 1, 2022

Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)

Recruiting
  • Refractory Follicular Lymphoma
  • Relapsed Follicular Lymphoma
  • Washington, District of Columbia
  • +2 more
Jul 6, 2022

Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)

Recruiting
  • Breast Neoplasms
  • Malignant Neoplasm of Breast
  • Dallas, Texas
    10 sites incl TX, WA, VA, and NV
May 16, 2022

Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

Not yet recruiting
  • Lymphoma, Mantle-Cell
  • +7 more
  • (no location specified)
Jun 21, 2022

Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Sacramento (Ibrutinib, Nivolumab)

Completed
  • Metastatic Renal Cell Cancer
  • Stage IV Renal Cell Cancer
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Feb 8, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Lung Cancer Trial in Houston (Ibrutinib)

Completed
  • Lung Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 21, 2021

Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Leukemia
  • Coral Gables, Florida
  • +8 more
Sep 28, 2022

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome Trial in

Completed
  • Myelodysplastic Syndrome
  • +4 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 11, 2021

Marginal Zone Lymphoma Trial in United States (Ibrutinib, Rituximab, Placebo)

Recruiting
  • Marginal Zone Lymphoma
  • Los Angeles, California
  • +12 more
Nov 29, 2022

Metastatic Solid Tumors Trial in San Francisco (PZP115891, PCI-24781)

Recruiting
  • Metastatic Solid Tumors
  • PZP115891, PCI-24781
  • San Francisco, California
    University of California, San Francisco
Aug 23, 2021

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (biological, drug, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in La Jolla (Venetoclax, Ibrutinib)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • La Jolla, California
    UC San Diego Moores Cancer Center
May 6, 2021

Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic

Withdrawn
  • CLL
  • +4 more
  • Treatment Free Observation
  • Basking Ridge, New Jersey
  • +8 more
Mar 4, 2022

High Risk Smoldering Multiple Myeloma Trial in New York (Ibrutinib)

Terminated
  • High Risk Smoldering Multiple Myeloma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 18, 2020

Lymphoma, Non-Hodgkin Trial in Worldwide (Ibrutinib, Rituximab, Ifosfamide)

Terminated
  • Lymphoma, Non-Hodgkin
  • Los Angeles, California
  • +76 more
Nov 7, 2022